Neuroimaging in Lewy body dementia

Area of Science:

• Neurology
• Radiology
• Medical Imaging

Background:

• Lewy body dementia (DLB) represents 30% of dementia cases in individuals over 65.
• Accurate early diagnosis of DLB remains challenging, particularly distinguishing it from Parkinson's disease dementia and Alzheimer's disease.
• Current diagnostic methods struggle with differentiating DLB from other neurodegenerative conditions.

Purpose of the Study:

• To review the current applications of neuroimaging in diagnosing Lewy body dementia (DLB).
• To highlight the role of various imaging modalities in supporting DLB diagnosis and differential diagnosis.
• To explore the potential of novel imaging techniques for understanding DLB pathophysiology and enabling earlier detection.

Main Methods:

• Review of established neuroimaging techniques including [123I]FP-CIT-SPECT, [18F]FDG PET, and [123I]MIBG molecular imaging.
• Discussion of structural imaging's role in excluding other causes and identifying DLB-specific atrophy patterns.
• Exploration of emerging PET imaging modalities like amyloid and tau imaging for DLB research.

Main Results:

• Established imaging techniques aid in supporting DLB diagnosis and differential diagnosis.
• Structural imaging is vital for ruling out alternative diagnoses and recognizing DLB-related atrophy.
• Novel PET imaging shows promise for deeper insights into DLB and earlier diagnostic capabilities.

Conclusions:

• Neuroimaging plays a critical role in the diagnosis and management of Lewy body dementia (DLB).
• A multimodal imaging approach, combining existing and novel techniques, is essential for advancing DLB understanding and diagnosis.
• Further research into advanced radioligands and imaging combinations may improve early detection and patient outcomes for DLB.